Information Provided By: 
Fly News Breaks for April 16, 2018
NEO
Apr 16, 2018 | 07:18 EDT
As reported earlier, BTIG analyst Sean Lavin upgraded NeoGenomics to Buy from Hold with a price target of $11. Lavin says the issues around exposure to Texas and Florida markets as well as lingering issues around Clarient have "largely dissipated". While the analyst remains concerned about the risk of "unexpected reimbursement changes", he adds that Medicare pricing for 2018 being in place cushions the risk around NeoGenomics guidance, while its growing Biopharma business and cost-cutting provide higher growth potential for the stock over time.
News For NEO From the Last 2 Days
There are no results for your query NEO
